Modulation der Glucagonrezeptorexpression

Patent europeic · EP2096170 · Stritgà

Inscripziun en il register

Numer da publicaziun
EP2096170
Numer da la dumonda
EP09007461
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
Stritgà
Scrittira da patent
Concedì
Annunzià
19-09-2006
Publitgà
02-09-2009
Concedì
10-08-2011
Stritgà
30-09-2011
Motiv
Taxa annuala betg pajada
Classas IPC
C12N 15/11 (2006.01)
A61K 31/712 (2006.01)
Prioritad
US 718684 P 19.09.2005
Derivà da
EP06814974
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 18-04-2012

    Stritgà, taxa betg pajada

    Published in Swissreg on 18.04.2012

  2. 10-08-2011

    Concedì

    Published in Swissreg on 10.08.2011

Partidas

Possessur

ISIS PHARMACEUTICALS, INC.

Isis Pharmaceuticals, Inc.

2855 Gazelle Court, Carlsbad, CA 92010, US

Inventur

Monia, Brett P.

Encinitas, CA 92024, US

Freier, Susan M.

San Diego, CA 92122, US

Bhanot, Sanjay

Carlsbad, CA 92009, US

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.